Holen Sie sich die Stockscreener-App
0.3696
3.33%
0.0119
Schlusskurs vom Vortag:
$0.3577
Offen:
$0.358
24-Stunden-Volumen:
999.98K
Relative Volume:
1.19
Marktkapitalisierung:
$19.34M
Einnahmen:
$65.27M
Nettoeinkommen (Verlust:
$-19.15M
KGV:
-0.5954
EPS:
-0.6208
Netto-Cashflow:
$-12.43M
1W Leistung:
+3.53%
1M Leistung:
+13.30%
6M Leistung:
-58.94%
1J Leistung:
-12.91%
1-Tages-Spanne:
$0.3501
$0.40
1-Wochen-Bereich:
$0.345
$0.40
52-Wochen-Spanne:
$0.2805
$1.32
Cosmos Health Inc Stock (COSM) Company Profile
Firmenname
Cosmos Health Inc
Sektor
Branche
Telefon
312-536-3102
Adresse
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.3695 | 19.38M | 65.27M | -19.15M | -12.43M | -0.6208 |
MCK
Mckesson Corp
|
810.87 | 102.28B | 397.96B | 4.55B | 9.64B | 34.77 |
COR
Cencora Inc
|
305.38 | 60.69B | 325.78B | 1.64B | 3.61B | 8.3139 |
CAH
Cardinal Health Inc
|
193.19 | 48.38B | 244.67B | 1.68B | 5.51B | 6.9487 |
HSIC
Henry Schein Inc
|
73.64 | 8.73B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
2.18 | 2.00B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc Aktie (COSM) Neueste Nachrichten
Cosmos Health projects Cur18 to generate $2.5M in U.S. revenue - Investing.com Canada
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months - Weatherford Democrat
A turmeric supplement is central to Cosmos Health's $2.5M U.S. sales bet - Stock Titan
Cosmos Health (COSM) price target increased by 50.00% to 4.59 - MSN
Cosmos Health Continues US Expansion with Q2 Launch of Cur18a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health - ACCESS Newswire
Cosmos Health (COSM) holder reports 4.14M shares, 8.15% stake in amendment - Stock Titan
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Produ - Palestineherald.com
73.5M Cosmos Health shares registered for resale (NASDAQ: COSM) - Stock Titan
Cosmos Health (COSM) Year-Ahead Outlook | Q4 2025: Below ExpectationsAcquisition - Xã Vĩnh Công
Is Cosmos Health (COSM) stock still a good play today | Q4 2025: Profit DisappointsReal-time Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Cosmos Health (COSM) Stock: Consolidation Phase Insight (Smart Money Flows) 2026-04-22Quantitative Analysis - Cổng thông tin điện tử tỉnh Lào Cai
COSM Stock Price, Quote & Chart | COSMOS HEALTH INC (NASDAQ:COSM) - ChartMill
Cosmos Health Introduces the "18 Series" in the United StatesA Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products - Finviz
This supplement line only launches products at exact clinical-trial doses - Stock Titan
Cosmos Health to begin Liv18 liver supplement production in April By Investing.com - Investing.com Australia
COSM earnings show rapid revenue growth - MSN
Cosmos Health to begin Liv18 liver supplement production in April - Investing.com
A U.S.-made liver supplement is central to Cosmos Health's $5M push - Stock Titan
Cosmos Health (COSM) Unveils Innovative Curcumin Supplement for U.S. Market - GuruFocus
Cosmos Health expands AI integration across operations By Investing.com - Investing.com Australia
Cosmos Health plans Q2 U.S. launch of curcumin supplement By Investing.com - Investing.com Australia
Cosmos Health plans Q2 U.S. launch of curcumin supplement - Investing.com
A turmeric supplement with 39x absorption heads to the U.S. in Q2 - Stock Titan
Trending Industry Today: Cosmos Health Leads Gains In ETH-Holding Companies Stocks - Moomoo
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Cosmos Health expands AI integration across operations - Investing.com
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30% - ACCESS Newswire
Record 2025 revenue and margin expansion at Cosmos Health (COSM) - Stock Titan
Cosmos Health Inc. 2025 Annual Report: Growth Strategy, Product Portfolio, and Global Healthcare Market Expansion - Minichart
Cosmos Health (COSM) Achieves Record Revenue and Significant Mar - GuruFocus
Cosmos 2025 10-K: $65.3M Revenue, $(0.63) EPS on net loss - TradingView
Cosmos Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cosmos Health (NASDAQ: COSM) expands pipeline, AI drug repurposing and equity funding - Stock Titan
Cosmos Health reports record revenue of $65.3 million in 2025 By Investing.com - Investing.com Australia
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Con - ACCESS Newswire
Cosmos Health reports record revenue of $65.3 million in 2025 - Investing.com
Cosmos Health Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cosmos Health receives third UAE order for 60,000 units By Investing.com - Investing.com Australia
Cosmos Health receives third UAE order for 60,000 units - Investing.com
Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units - ACCESS Newswire
A third UAE reorder lifts Cosmos Health product demand to 270,000 units - Stock Titan
Finanzdaten der Cosmos Health Inc-Aktie (COSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cosmos Health Inc-Aktie (COSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Siokas Grigorios | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.41 |
291,262 |
120,000 |
8,473,382 |
| Siokas Grigorios | Chief Executive Officer |
Jan 23 '26 |
Buy |
0.50 |
90,325 |
45,000 |
8,182,120 |
| Siokas Grigorios | Chief Executive Officer |
Jan 20 '26 |
Buy |
0.50 |
353,321 |
175,000 |
8,091,795 |
| Siokas Grigorios | Chief Executive Officer |
Jan 14 '26 |
Buy |
0.45 |
493,495 |
220,000 |
7,738,474 |
| Siokas Grigorios | Chief Executive Officer |
Jan 12 '26 |
Buy |
0.50 |
113,185 |
57,000 |
7,244,979 |
| Siokas Grigorios | Chief Executive Officer |
Jan 08 '26 |
Buy |
0.52 |
156,190 |
81,000 |
7,131,794 |
| Siokas Grigorios | Chief Executive Officer |
Jan 07 '26 |
Buy |
0.52 |
124,880 |
65,000 |
6,975,604 |
| Siokas Grigorios | Chief Executive Officer |
Jan 06 '26 |
Buy |
0.54 |
133,953 |
72,000 |
6,850,724 |
| Siokas Grigorios | Chief Executive Officer |
Dec 19 '25 |
Buy |
0.49 |
88,314 |
43,000 |
6,716,771 |
| Siokas Grigorios | Chief Executive Officer |
Dec 15 '25 |
Buy |
0.42 |
168,472 |
70,000 |
6,628,457 |
0.00%
2.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):